FISH detection of HER-2/neu oncogene amplification in early onset breast cancer

Breast Cancer Research and Treatment

Volumn 39, Issue 2, 1996, Pages 203-212

  Xing, Wei Rong ^a   Gilchrist, Kennedy W ^b   Harris, Charles P ^d   Samson, Wilner ^c   Meisner, Lorraine F ^b,c,d  

^a Natl Eval Ctr Toxicol Fertil D   (China)

^b Department of Pathology ^*  (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

Author keywords

Archival specimens; Breast cancer recurrence; Breast carcinoma in women under 40; c erbB 2; Disease free survival; Fluorescent in situ hybridization; HER 2 neu amplification; Prognostic indicators

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; ONSET AGE; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0029788433     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806187     Document Type: Article

References (40)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
2. Klijn JG, Berns EM, Bontenbal M, Foekens J: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treatment Reviews 19 (Supplement B): 45-63, 1993
3. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fourney RM: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Research 51: 556-567, 1991
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
5. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Research 49: 6675-6679, 1989
6. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk G, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Research 53: 4960-4970, 1993
7. Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL: Expression of HER-2/neu oncoprotein in human breast cancer: A comparison of immunohistochemical and Western blot techniques. Anticancer Research 12(6B): 1965-1971, 1992
8. Descotes F, Pavy JJ, Adessi GL: Human breast cancer: Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Research 13: 119-124, 1993
9. Babiak J, Hugh J, Poppema S: Significance of c-erbB-2 amplification and DNA aneuploidy. Cancer 70: 770-776, 1992
10. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koemer F, Cirrincione CT, Budman DR, Wood WC, Barcos M: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Eng J Med 330: 1260-1266, 1994
11. Wolman SR, Pauley RJ, Mohamed AN, Dawson PJ, Visscher DW, Sarker FH: Genetic markers as prognostic indicators in breast cancer. Cancer 70 (Supplement): 1765-1774, 1992
12. Prost S, Le MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guerin M, Riou G: Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 58: 763-768, 1994
13. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777, 1994
14. Farkas DH, McMahon LW, Cai P, Umek RM: Improved quantitation of HER-2/neu gene copy number in breast tumor-derived DNA samples. Am J Clin Path 100: 444-450, 1993
15. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M: c-erb-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833-838, 1991
16. Pechoux C, Chardonnet Y, Noel P: Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions. Anticancer Res 14: 1343-1360, 1994
17. Mansour EG, Ravdin PM, Dressier L: Prognostic factors in early breast carcinoma. Cancer 74(Supplement): 381-400, 1994
18. Hankey BF, Miller B, Curtis R, Kosary C: Trends in breast cancer in younger women in contrast to older woman. Journal of the National Cancer Institute Monographs (16); 7-14, 1994
19. Swanson GM, Lin CS: Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. Journal of the National Cancer Institute Monographs (16): 69-77, 1994
20. Bowcock AM: Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer. Breast Cancer Research and Treatment 28: 121-135, 1993
21. Bischoff FZ, Hansen MF: Genetics of familial breast cancer. The Cancer Bulletin 45: 476-482, 1993
22. Easton D, Ford D, Peto J: Inherited susceptibility to breast cancer. Cancer Surveys 18: 95-113, 1993
23. Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials? Journal of the National Cancer Institute Monographs (16): 35-42, 1994
24. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039-1043, 1993
25. Lee W, Han K, Harris CP. Meisner LF: Detection of aneuploidy and possible deletion in paraffin-embedded rhabdo-myosarcoma cells with FISH. Cancer Genetics and Cytogenetics 68: 99-103, 1993
26. Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG: Amplification of HER-2/neu (erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 40: 35-39, 1993
27. Watatani M, Nagayama K, Imanishi Y, Kurooka K, Wada T, Inui H, Hirai K, Ozaki M, Yasutomi M: Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. Breast Cancer Research and Treatment 28: 231-239, 1993
28. Nagai MA, Marques LA, Torloni H, Brentani MM: Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50: 412-417, 1993
29. Lee W, Han K, Drut RM, Harris CP, Meisner LF: Use of FISH for retrospective detection of aneuploidy in multiple myeloma. Genes Chromosomes and Cancer 7:137-143, 1993
30. Han K, Lee W, Harris CP, Kim W, Shim S, Meisner LF: Quantifying chromosome changes and lineage involvement in myelodysplastic syndrome (MDS) using fluorescent in situ hybridization (FISH). Leukemia 8: 81-86, 1994
31. Allred DC, Clark GM, Elledge CR, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. Journal of the National Cancer Institute 88: 200-206, 1993
32. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Research and Treatment 32: 39-47, 1994
33. King MC, Rowell S: Genetic analysis of breast and ovarian cancer in families. In: Dickson RB, Lippman ME (eds) Mammary Tumorigenesis and Malignant Progression. Kluwer Academic Publishers, Boston/Dordrecht/London, 1994, p 51
34. Keyhani-Rofagha S, O'Toole RV, Farrar WB, Sickle-Santanello B, DeCenzo J, Young D: Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 65: 1577-1581, 1990
35. Gilchrist KW, Gray R, van Driel-Kulker A, Mesker WE, Ploem-Zaaijer JJ, Ploem JS, Taylor SG, Tormey DC: High DNA content and prognosis in lymph node positive breast cancer. A case control study by the university of Leiden and ECOG. Breast Cancer Research and Treatment 28: 1-8, 1993
36. Batsakis JC, Sneige N, el-Naggar AK: Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer. Cancer 71 (Supplement): 2152-2153, 1993
37. Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL, Wold LE, Grant C, Gonchoroff NJ, Katzmann JA: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer 74: 1752-1761, 1994
38. Loprinzi CL, Ravdin PM, Laurentiis M, Novotny P: Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? Journal of Clinical Oncology 12: 1422-1426, 1994
39. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl Med 326: 1756-1761, 1992
40. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM: Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 70 (Supplement): 1775-1781, 1992